Charlotte Xu 's Blog

My program:

LIBNAME mydata “/home/u41173977/my_courses/ldierker” access=readonly; DATA new;set mydata.nesarc_pds; LABEL S3CQ14A3 = “presence or absence of drug abuse”; LABEL S3EQ1 = “Father has drug abuse”; LABEL S3EQ2 = “Mother has drug abuse”; /*if one of parent has problem with drug abuse*/ IF S3EQ1=1 or S3EQ2=1; PROC SORT;by IDNUM;

PROC FREQ; TABLE S3CQ14A3 S3EQ1 S3EQ2 ; RUN;

Below snapshot are the output.

I am investing if family history has positive impact on drug abuse. So I pick up two variables which present the number of people whose father or mother has drub abuse problem individually. 

The results show if one of parent has drug abuse issue, their children has 27.4% possibility have drug abuse problem too. It is not a small percentage and indicate parents has impact on children if they have drub abuse issue.   

By looking at the data output of father and mother with drug abuse, the number of father show higher percentage 69.71% by comparing number in mother 47%. It present husband and wife has significant impact each other.

The missing frequency is 718, the samples may present the part of people don’t know or did not take drug ever.

I am interested in people health. After looking through the codebook for the NESARC study, I have decided that I am particularly interested in Drug Abuse. 

I will choose the dataset of NESARC surely. The original research topic is drug abuse.

I will pickup below two sections in my personal codebook

SECTION 3C: DRUG ABUSE/DEPENDENCE (MEDICINE EXPERIENCES) SECTION 3E: FAMILY HISTORY (II) OF DRUG ABUSE

While drug abuse is a good starting point, I need to determine what it is about drug abuse that I am interested in. As I know , one of friends that I have known through the years that hooked on drugs heavily. She is tend to take drugs even it is not necessary and suggest others to do so even the effect is unclear. Meanwhile her mother show same behavior. It seems that the behavior is related with family aggregation.

I decide that I am most interested in exploring the association between family history and drug abuse. 

So the 2nd research topic is to find out the association between family aggregation and age of drug abuse.

The variables I used:

Age of drug abuse ----

1378-1379 S3CD1Q13A AGE AT ONSET OF SEDATIVE ABUSE 1380-1381 S3CD2Q13A AGE AT ONSET OF TRANQUILIZER ABUSE

1382-1383 S3CD3Q13A AGE AT ONSET OF OPIOID ABUSE 1384-1385 S3CD4Q13A AGE AT ONSET OF AMPHETAMINE ABUSE 1386-1387 S3CD5Q13A AGE AT ONSET OF CANNABIS ABUSE 1388-1389 S3CD6Q13A AGE AT ONSET OF COCAINE ABUSE 1390-1391 S3CD7Q13A AGE AT ONSET OF HALLUCINOGEN ABUSE 1392-1393 S3CD8Q13A AGE AT ONSET OF INHALANT ABUSE 1394-1395 S3CD9Q13A AGE AT ONSET OF HEROIN ABUSE

1396-1397 S3CD10Q13A AGE AT ONSET OF OTHER DRUG ABUSE

Family aggregation on problems with drugs -----

2429-2429 S3EQ1 BLOOD/NATURAL FATHER EVER HAD PROBLEMS WITH DRUGS

2430-2430 S3EQ2 BLOOD/NATURAL MOTHER EVER HAD PROBLEMS WITH DRUGS

2433-2433 S3EQ3C ANY FULL BROTHERS EVER HAD PROBLEMS WITH DRUGS

2436-2436 S3EQ4C ANY FULL SISTERS EVER HAD PROBLEMS WITH DRUGS

Literatural review: I am checking relevent information and stuies in ” https://scholar.google.com” by searching item ”family histoy of drug abuse”.

reference: “Family History of Alcohol and Drug Abuse, Childhood Trauma, and Age of First Drug Injection ″ by  Chris Taplin,Sahoo Saddichha,Kathy Li &Michael R. Krausz https://www.tandfonline.com/doi/full/10.3109/10826084.2014.901383

″ Familial Transmission of Substance Use Disorders ″ by  Kathleen R. Merikangas, PhD; Marilyn Stolar, MA; Denise E. Stevens, PhD; et al https://jamanetwork.com/journals/jamapsychiatry/fullarticle/204407

After literatural review, I found there is increasing evidence that substance use disorders are familial and that genetic factors explain a substantial degree of their familial aggregation.According to the article ” Familial Transmission of Substance Use Disorders” , it presnts that elevation in risk of this magnitude places a family history of drug disorder as one of the most potent risk factors for the development of drug disorders.